US Pharma MarketingLilly, Hanmi sign $1.26bn licensing deal for sonefpeglutide
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide excluding Korea. Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals. Hanmi will continue its global Phase II trial in SBS while Lilly will further clinical development using available data. Credit: Premreuthai / Shutterstock.com. Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2…
Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide excluding Korea.
Source: Pharmaceutical Technology